-

IFF Expands Pet Portfolio with Latest Science-driven Solutions

Advanced biotechnology and innovative solutions set to redefine pet health and wellness

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global powerhouse in bioscience and innovation, today announced a groundbreaking expansion of its pet portfolio. This launch marks a significant leap in IFF’s mission to revolutionize companion animal care through advanced biotechnology and innovation.

“We're excited to bring our world-class bioscience into the pet wellness space," said Dr. Jordon Gruber, companion animal technical leader, Health & Biosciences, IFF. “Our new portfolio empowers brands to tackle key challenges, delivering standout products that enhance pet health and wellness in a competitive marketplace. From improving gut health and dental care to hydration and reducing odors, we are setting a new benchmark.”

Leveraging decades of expertise in human and animal wellness, IFF integrates flavors, functional technologies, processing aids, and ingredients into a cohesive ecosystem designed to drive industry innovation.

IFF’s Pet Solutions are supported by specialized R&D centers, including the Pet Translational Research Lab (Wilmington, DE), Pet Enzymes Lab (Brabrand, Denmark), and Pet Applications Lab (New Century, KS). These centers advance clinical science and application research, ensuring every ingredient and solution is backed by real data and impactful results.

The Company’s latest innovation focuses on enzyme-driven palatability with clean-label appeal, sustainable ingredients for cost-effective production, and functional health technologies to support full pet life cycle. The newly launched solutions include:

  • Microsource™ CA ─ an innovative, microbiome-enhancing product for improved cat litter management, with four times less fecal ammonia odors after 7 days1, ensuring a cleaner and healthier environment without harsh chemicals.
  • Betafin® Pet ─ a natural betaine supporting hydration, gut health and overall wellness for both dogs and cats.

Other solutions from the portfolio includes enzymes, probiotics, plant protein and food protection solutions, natural colors, and flavor solutions based on proprietary flavor technology.

“This launch is more than the products; it's about transforming the way we approach pet wellness,” said Brett Volmert, senior marketing leader for Pets in North America, Food Ingredients, IFF. “Pet parents are increasingly focused on their pets' health, and manufacturers require innovative, science-backed solutions, and a good understanding of functionality to meet this demand.”

IFF's Pet Solutions are available across the U.S., empowering brands to elevate their offerings and meet the rising demand for smarter, more sustainable pet care. The new portfolio will be showcased at IFF’s booth 2707 at the Petfood Forum, April 28-30, Kansas Convention Center. Learn more about IFF Pet Solutions here.

1 IFF internal data

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contacts

Jasmine Chia
Global Communications Director, Food Ingredients
+65 9827 3808
Jasmine.Chia@iff.com

International Flavors & Fragrances

NYSE:IFF

Release Versions

Contacts

Jasmine Chia
Global Communications Director, Food Ingredients
+65 9827 3808
Jasmine.Chia@iff.com

More News From International Flavors & Fragrances

IFF Announces Tender Offers for Certain Outstanding Series of Notes

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Tre...

IFF Declares Dividend for Second Quarter 2025

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—adva...

IFF Completes Divestiture of Pharma Solutions Business Unit

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its Pharma Solutions business unit to Roquette. “The completion of our Pharma Solutions divestiture represents a significant milestone for IFF as we delivered our targeted net debt to credit-adjusted EBITDA of below 3.0x,” said Erik Fyrwald, IFF CEO. “This is an important step as it allows us to focus on our core strategy – capitalizing on the exciting growth opp...
Back to Newsroom